Will a Renaissance in Immunotherapy Become
Part of the Paradigm of Cancer Care?
Inundated with all the predictions of what cancer care will
look like in the future, it would be easy for us to speculate on
what may transpire and how we will get there. It remains to
be seen how soon some of the futuristic visions may become
reality. For example, in one such scenario, involving a newly diagnosed kidney cancer, a patient is studied in a trial involving two new drugs attached to a microscopic “nanoparticle shuttle” that will deliver them directly to individual cancer cells, sparing healthy cells and minimizing side effects. To read all of the Editor's Memo, click here.
To read features and articles in the journal, click on the titles below.
Medical Intelligence Tracking Trends From Web-based Sources, Translational Research,
the FDA, and Patient Registries
Journal Club Essential Peer-Reviewed Reading in Kidney Cancer
To view the complete issue of Kidney Cancer Journal, click here
Click the arrow to read more...
Argos Therapeutics to Initiate Late-Stage Trial
for AGS-003 in Combination With Sunitinib
in Metastatic RCC
DURHAM, NC—Argos Therapeutics, Inc., is planning to initiate a phase 3 clinical trial, referred to as the ADAPT study, to evaluate the combination of AGS-003 with sunitinib in patients with newly diagnosed, previously untreated, metastatic RCC (mRCC).
Tivozanib demonstrates superiority over sorafenib in patients with advanced renal cell cancer in Phase 3 TIVO-1 trial
CAMBRIDGE, MA —AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma (RCC).
FDA Approves INLYTA® (axitinib) for Patients
With Previously Treated Advanced RCC
NEW YORK—The spectrum of therapy in kidney cancer has expanded to 7 drugs with the FDA approval of INLYTA® (axitinib), a tyrosine kinase inhibitor.
EDITOR'S MEMO
